Sabby Management’s Oasmia Pharmaceutical AB OASM Stock Holding History

Sabby Management’s Portfolio OASM Stock Details OASM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-19,000	Closed	-$17K	–	219
2017 Q4	$17K	Hold	19,000	–	–	﹤0.01%	154
2017 Q3	$20K	Hold	19,000	–	–	﹤0.01%	160
2017 Q2	$20K	Sell	19,000 -16,054	-46%	-$28.3K	﹤0.01%	211
2017 Q1	$66K	Buy	+35,054	New	+$82.2K	﹤0.01%	244
2016 Q2	–	Sell	-477,836	Closed	-$2.02M	–	364
2016 Q1	$2.02M	Sell	477,836 -185,302	-28%	-$657K	0.1%	99
2015 Q4	$2.4M	Buy	+663,138	New	+$2.61M	0.13%	107

Other funds holding OASM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sabby Management's OASM Position: Q1 2018 in Review

Sabby Management sold out of Oasmia Pharmaceutical AB (OASM) in Q1 2018, closing a stake of 19,000 shares — an estimated $17K sold.

Sabby Management first reported a position in OASM in Q4 2015 and held it in 6 quarters. The position peaked at $2.4M in Q4 2015. 4 funds tracked by Wall St. Rank hold OASM as of Q1 2018.

Sabby Management reported no remaining Oasmia Pharmaceutical AB position as of Q1 2018 after selling out during the quarter.
Sabby Management sold 19,000 Oasmia Pharmaceutical AB shares in Q1 2018, an estimated $17K.
Sabby Management first reported a position in Oasmia Pharmaceutical AB in Q4 2015 and held it in 6 quarters.
Sabby Management's Oasmia Pharmaceutical AB position peaked at $2.4M in Q4 2015.
4 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.